2011•Medical Journal of National Defending Forces in Northwest ChinaRequires access

Clinical effect of telbivudine in 53 patients with HBeAg-positive chronic hepatitis B

WU Weiqiang

Abstract

Objective:To evaluate the clinical effect of telbivudine in patients with HBeAg-positive chronic hepatitis B(CHB).Methods: The level of serum alanine aminotransferase(ALT),HBV DNA,HBeAg loss,HBeAg seroconversion and genotype resistance of 53 patients with HBeAg-positive treated with telbivudine were compared.The average course of treatment was 22.2 months.Results:The rates of serum undetectable HBV DNA,normalization of ALT,HBeAg loss,HBeAg seroconversion and genotype resistance were 66.0%,83.7%,73.6%,13.2% and 9.4% respectively.Conclusion:Telbivudine was effective in patients with HBeAg-positive chronic hepatitis B.

About this research paper

What this paper is about

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Key concepts: Telbivudine, HBeAg, Medicine, Gastroenterology, Chronic hepatitis, Internal medicine, Genotype, Seroconversion